Editorially independent content, supported with advertising
08.08.24
Is avacincaptad pegol (Izervay, Astellas) effective in patients with major ellipsoid zone attenuation at baseline? Katherine Talcott, MD, stopped by our studio in Stockholm during ASRS with a top-line summary of her lecture at this year’s meeting. And Sunir Garg, MD, joined us for a conversation about the GALE study, which assessed 36 months of continuous dosing of pegcetacoplan (Syfovre, Apellis Pharmaceuticals). What did microperimetry findings reveal about long-term dosing with C3 inhibition? Join us in this episode to find out.
08.21.25
ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human GradersJohn Kitchens, MD; Krishna Mukkamala, MD
06.12.25
Duke AVS Clips: PVR, DR, Imaging, and MTMJason Hsu, MD; Majda Hadziahmetovic, MD; Aleksandra Rachitskaya, MD; Gavin Tan, MD, PhD, FRCSed
06.09.25
Duke AVS Clips: Pediatrics, Anesthesia Trends, and AILejla Vajzovic, MD; Jason Fan, MD; Glen J. Jaffe, MD
06.05.25
Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDsAvni P. Finn, MD, MBA; Lejla Vajzovic, MD, MBA; David Zacks, MD, PhD; Dilraj S. Grewal, MD; Xi Chen, MD, PhD; Yuxi Zheng, MD; Durga Borkar, MD; and Yannek I. Leiderman, MD, PhD
05.29.25
ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation DataMarion Munk, MD, PhD; and Diana Do, MD
05.22.25
ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the PipelineDavid Miller, MD; and Robert Wang, MD
12.05.24
AAO '24: Real-world PDR Treatment vs. Protocol S Guidelines, and Retinal Imaging for Alzheimer'sAdrienne Scott, MD; and Dilraj Grewal, MD
11.14.24
AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GADurga S. Borkar, MD, MMCi; and Alex Melamud, MD
11.07.24
AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMDJeremiah Brown, MD, MS; and Eric Schneider, MD
10.31.24
AAO '24: COVID and Retinal Disease, Plus the Latest on Step Therapy and Declining ReimbursementRahul Khurana, MD; and Paul Hahn, MD, PhD
Show More